X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AUROBINDO PHARMA LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

AUROBINDO PHARMA LIMITED  (AUBD)


Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
aurobindo pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 671.5       No. of shares m 585.17
    Mkt Cap Rs m 392,912       % ch % -1.2
    Vol '000 141.9       % ch week % -1.1
    P/E X 16.9       % ch 1-mth % -0.8
    P/CF X 16.6       % ch 12-mth % -8.7
    EPS (TTM) Rs 39.7       52 week H/L Rs 895.0/622.0
(As on Mar 29, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs2062055451,2801,541 
Low Rs80100139509582 
Sales per share (Unadj.) Rs159.0201.1277.9415.1237.5 
Earnings per share (Unadj.) Rs-4.210.140.254.033.9 
Diluted earnings per shareRs-2.15.020.026.933.9 
Cash flow per share (Unadj.) Rs2.618.651.065.440.6 
Dividends per share (Unadj.) Rs1.001.503.004.502.50 
Adj. dividends per shareRs0.500.751.492.252.50 
Dividend yield (eoy) %0.71.00.90.50.2 
Book value per share (Unadj.) Rs80.489.5128.7176.6120.6 
Adj. book value per shareRs40.044.564.188.1120.6 
Shares outstanding (eoy) m291.12291.21291.46291.98585.17 
Bonus/Rights/Conversions  ----PREF 
Price / Sales ratio x0.90.81.22.24.5 
Avg P/E ratio x-33.715.18.516.631.3 
P/CF ratio (eoy) x54.08.26.713.726.2 
Price / Book Value ratio x1.81.72.75.18.8 
Dividend payout %-23.614.97.58.37.4 
Avg Mkt Cap Rs m41,63044,35199,577261,147621,041 
No. of employees `0008.68.89.511.613.3 
Total wages/salary Rs m5,3576,6338,02413,02315,508 
Avg. sales/employee Rs Th5,358.96,653.88,526.110,469.510,457.6 
Avg. wages/employee Rs Th620.4753.8844.71,124.91,167.1 
Avg. net profit/employee Rs Th-143.0333.91,234.61,361.11,491.6 
  INCOME DATA
Net Sales Rs m46,27458,55380,998121,205138,961 
Other income Rs m2472852169671,663 
Total revenues Rs m46,52158,83981,214122,172140,624 
Gross profit Rs m5,6138,61021,33725,63632,056 
Depreciation Rs m2,0052,4873,1253,3263,926 
Interest Rs m2,7722,6663,1021,5992,568 
Profit before tax Rs m1,0823,74115,32521,67927,225 
Minority Interest Rs m625384539 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-3,2120000 
Tax Rs m-8888273,6355,9667,444 
Profit after tax Rs m-1,2352,93911,72915,75819,820 
Gross profit margin %12.114.726.321.223.1 
Effective tax rate %-82.122.123.727.527.3 
Net profit margin %-2.75.014.513.014.3 
  BALANCE SHEET DATA
Current assets Rs m32,64041,36856,31282,988100,015 
Current liabilities Rs m29,15134,30842,20061,36474,759 
Net working cap to sales %7.512.117.417.818.2 
Current ratio x1.11.21.31.41.3 
Inventory Days Days122120107109107 
Debtors Days Days98100119107110 
Net fixed assets Rs m28,40128,57427,36641,09852,350 
Share capital Rs m291291292292585 
"Free" reserves Rs m22,62425,06235,80249,86767,707 
Net worth Rs m23,39726,05837,50251,55970,567 
Long term debt Rs m9,64611,48312,79413,6158,472 
Total assets Rs m62,37672,77894,898129,145156,994 
Interest coverage x1.42.45.914.611.6 
Debt to equity ratio x0.40.40.30.30.1 
Sales to assets ratio x0.70.80.90.90.9 
Return on assets %2.57.715.613.414.3 
Return on equity %-5.311.331.330.628.1 
Return on capital %2.017.136.735.837.7 
Exports to sales %63.266.165.851.651.0 
Imports to sales %31.831.226.719.218.8 
Exports (fob) Rs m29,24038,71053,26962,51470,927 
Imports (cif) Rs m14,69918,27921,60723,27226,193 
Fx inflow Rs m29,78039,05653,42062,61371,015 
Fx outflow Rs m18,31219,44623,25125,32928,799 
Net fx Rs m11,46819,61030,16937,28442,216 
  CASH FLOW
From Operations Rs m 3,263 2,749 6,463 12,368 17,596 
From Investments Rs m -5,632 -2,463 -8,187 -13,980 -13,801 
From Financial Activity Rs m 1,189 1,081 1,176 932 -198 
Net Cashflow Rs m -1,181 1,366 -548 -680 3,597 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for aurobindo pharma limited

 Share Holding
Indian Promoters : 54.1%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 8.0%
FIIs : 27.7%
ADR/GDR : 0.0%
Free float : 10.2%
Shareholders : 69,601
Pledged promoter(s) holding : 8.6%
 Company Information
Top
    REGD OFF: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
    E-MAIL: cs@aurobindo.com     WEB: www.aurobindo.com
    TELEPHONE: (040) 6672 5333     FAX: (040) 2374 1080
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
    AUDITOR: S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.4

More pharmaceuticals Company Fact Sheets:   RANBAXY LABPANACEA BIOTECHGSK PHARMASUVEN LIFEORCHID PHARMA LTD


Today's Market

Sensex Finishes Firm; Automobile Stocks Fall on SC Verdict(Closing)

Indian share markets finished the trading day on a positive note. At the closing bell, the BSE Sensex closed higher by 122 points, whereas the NSE Nifty finished higher by 43 points.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Why Real Estate Prices are Going Down at a Slow Pace(Vivek Kaul's Diary)

Mar 23, 2017

Many investors have got anchored to a selling price which has got nothing to do with the current state of the real estate market

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

Bad Loans Inventory Bloats Up(Chart Of The Day)

Mar 18, 2017

This is why RBI's new strategy is ineffective to deal with bad debt menace.

More

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TEVA PHARMA COMPARISON

Compare Company With Charts

COMPARE AUROBINDO PHARMA WITH

MARKET STATS